You are being disingenuous - there were two aspects of the study. The pain reduction was significant and has been previously pointed out, the results were statistical significant.
With the opioid crisis in America and millions in fines, a study that it shown to reduce pain and have no side effects will be looked at very favourable. Yes, patients who at 68 months and have scar tissue may not have a statistical benefit and be able to touch their toes, but for those who received the cells in 24 months will have statistical significance.
I am sure there is a huge market for those who have been suffering LBP for 12-60 months, and they will be very happy to be given cells.
As SI said the commercial partners will seek to partner for this in America with a massive upfront payment. Or are you saying that there will be no commercial partners for this?
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-168
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
-0.045(4.52%) |
Mkt cap ! $1.093B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 94.5¢ | $2.002M | 2.066M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 55888 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.5¢ | 43431 | 21 |
View Market Depth
| Last trade - 14.50pm 20/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |